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Abstract--Activation of the mitogen activated protein kinase (MAPK) plays esential roles in many signal trans- 
duction pathways. MAPK has been demonstrated to phosphorylate and regulate numerous cellular proteins, includ- 
ing growth factor receptor, transcription factors, cytoskeletal proteins, phospholipase and other protein kinases. 
Activation of MAPK requires phosphorylation of both threonine and tyrosine residues, which are catalysed by a 
single protein kinase known as MAPK kinase or MEK. MEK itself is activated by phosphorylation on two con- 
served serine residues. Three distinct mammalian Ser/Thr kinases, including Raf, Mos and MEKK (for MEK 
kinase), have been demonstrated to phosphorylate and activate MEK. The MAP kinase cascade is highly conserved 
in all eukaryotes and involved in numerous cellular responses. Activation of MAPK is a transient event that is tight- 
ly regulated by both kinases and phosphatases. A growth factor induced dual specific phosphatase is likely to play 
an important role in MAPK regulation: 
Key words: Kinase; phosphatase; MEK; MAPK; ERK. 
Phosphorylat ion of cellular proteins plays an 
important role in the control of cell growth and 
differentiation induced by growth factors and 
oncogenes. Numerous serine/threonine kinases 
have been identified that may catalyse these reac- 
tions. One of the most promising candidates dis- 
covered is the family of enzymes known as mito- 
gen activated protein kinase (MAPK) or extracel- 
lu lar  s ignal  r egu la ted  k inase  (ERK)  [1-4] .  
Activation of MAPK is a common event in many 
signal transduction pathways. The kinase cascade 
leading to MAPK activation is highly conserved 
Abbreviations: ERK--extracellular signal regulated kinase; 
GAP----GTPase activating protein; MAPK--mitogen activated 
protein kinase; MEK--MAP kinase kinase. 
through evolution and has been found in yeast, C. 
elegans, Drosophila, and mammals [1-7]. The 
activity of MAPK is acutely stimulated by virtually 
every mitogenic stimulus, including growth fac- 
tors with tyrosine kinase receptors, cytokines, T 
cell antigens, hormones that bind to G protein 
coupled receptors, and phorbol esters, suggesting 
that this pathway is likely to represent a site of 
integration for common signalling mechanism in 
cellular regulation [ 1-5]. 
THE PATHWAY 
Ray and Sturgill  ini t ial ly d i scovered  that 
insulin stimulated a rapid activation of a cellular 
serine/threonine protein kinase which is widely 
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known as MAPK or ERK [8]. In fact, the same 
kinase was activated by many extracellular signals 
in addition to insulin [2]. This kinase activity 
itself is regulated by phosphorylation. Anderson et 
al. demonstrated that MAPK activation requires 
both tyrosine and threonine phosphorylation [9]. 
These observations led to the initial excitement 
that activation of MAPK may integrate multiple 
signalling events involving activation of tyrosine 
and serine/threonine kinases. However, subse- 
quent studies demonstrated that MAPK is in fact 
activated by a single protein kinase, MEK (for 
MAPK or ERK kinase), which activates MAPK 
by phosphorylation of both threonine and tyrosine 
[10-13]. 
Recent studies of the mitogenic growth factor 
signal transduction and ras function have elucida- 
ted a linear pathway from ligand binding to 
MAPK activation and alteration of cellular activi- 
ties (Fig. 1). The best understood system is the 
pathway involving the mitogenic growth factors. 
Receptors for growth factors have intrinsic tyro- 
sine kinase activity which is activated by binding 
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Fig. 1. Signal transduction pathway of mitogentic 
growth factors and MAPK. 
of ligands [14]. In the case of epidermal growth 
factor receptors, EGF causes a dimerization and 
tyrosine autophosphorylation of its receptor [14]. 
The au tophosphory la ted  EGF receptor  then 
recruits several signalling molecules which bind 
to the growth factor  receptor  via their  SH2 
domains. SH2 domain is a structural motif fre- 
quently found in signalling molecules and specifi- 
cally recognizes phosphotyrosine and neighbour- 
ing sequences. One of the associating molecules is 
a protein called Grb2 (for growth factor receptor 
binding protein 2) which binds to the receptor in a 
ligand dependent manner [15]. Grb2 not only con- 
tains a SH2 domain but also contains two SH3 
domains. Experiments from several laboratories 
have demonstrated that the SH3 domains of Grb2 
directly associate with a proline rich region in the 
Sos molecule which is a guanidine nucleiotide 
exchange protein [15-22]. Sos was initially identi- 
fied in Drosophila to be downstream of the 
Sevenless receptor tyrosine kinase and upstream 
of ras gene in eye development [22-25]. Sos can 
facilitate the conversion of Ras-GDP, an inactive 
form of Ras, to Ras-GTP which is the active form 
of Ras. Genetic evidence from C. elegans shows 
that the sem-5 gene product (a Grb2 homolog) 
plays essential roles in the vulva induction and 
sex myoblast migration [26]. The vulva develop- 
ment in C. elegans is regulated by the let-23 
receptor tyrosine kinase. Therefore, both genetic 
and biochemical studies support that Grb2 and 
Sos function between the tyrosine kinase and Ras 
protein. The discovery of Grb2 and Sos and their 
interaction with tyrosine kinase receptors and Ras 
made the direct connection of growth factor bind- 
ing and activation of Ras [27]. 
This basic scheme is employed  by other  
growth factor receptors although a slightly altered 
signal transduction pathway is used for each spe- 
cific growth factor. For example, IRS1 (insulin 
receptor substrate 1) serves as a molecular dock- 
ing adaptor rather than the tyrosine kinase recep- 
tor  i t se l f  during insulin s t imulat ion [28]. 
Furthermore, Shc2, a SH2 and SH3 containing 
molecule, appears to mediate the initial interaction 
with IRS 1 instead of Grb2 [29]. Other SH2 con- 
taining molecules such as SYP, a SH2 containing 
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tyrosine phosphatase, can directly associate with 
autophosphorylated EGF receptor then lead to the 
association of Grb2 and activation of Ras [30]. 
Nck is another SH2 and SH3 containing molecu- 
lar adaptor which binds to autophosphorylated 
PDGF receptor [31 ]. 
The Ras protein has been known for a long 
time to be a molecular switch regulating cell 
growth [32]. However, the connection between 
Ras activation and cell proliferation is not clear 
although the GTPase activating protein (GAP) has 
been suggested as a putative downstream effector 
molecule of Ras [33]. A significant breakthrough 
came from the study of Ras and Raf interaction. 
Moodie et al. reported that the immobilized Ras- 
GTP can serve as an affinity ligand to purify Raf 
protein [34]. These data provided the first evi- 
dence that Ras and Raf might interact with each 
other. Similar experiments have been performed 
in yeast using the two-hybrid system, and have 
shown that Raf and Ras can associate in vivo 
[35-37]. Both biochemical and genetic experi- 
ments have demonstrated that the Ras-GTP but 
not Ras-GDP interacts with Raf either directly or 
indirectly. It is the N-terminal domain of Raf 
required for interaction with Ras. Furthermore, 
Raf has been demonstrated to directly phosphory- 
late and activate the MAP kinase kinase (MEK) 
[38-40]. These observations made a direct con- 
nection from ras to the MAPK kinase cascade. 
However, this signal transduction pathway is far 
from complete. The most serious defect of this 
scheme is that no direct evidence is available to 
demonstrate that association of Raf with Ras-GTP 
activates the Raf kinase activity. Therefore, the 
significance of Ras-Raf association in Raf activa- 
tion remains to be elucidated. 
How the signal crosses the nuclear envelope is 
not fully understood. However, MAPK is likely to 
play an important role in this process. MAPK can 
phosphorylate and activate the p90 rsk which can 
translocate into cell nucleus upon mitogen stimu- 
lation [41]. Several MAPK substrates are nuclear 
transcription factors, including p60 ~cF, c-jun and 
c-myc [42-44] .  MAPK translocates into the 
nucleus when cells are stimulated by mitogens 
[41]. Therefore ,  the nuclear translocation of  
MAPK is consistent with a role in signal transduc- 
tion from the cytoplasm to the nucleus. 
MAPK can be activated by numerous extracel- 
lular signals. Activat ion of  MAPK has been 
observed with hormone binding to trimeric G-pro- 
tein coupled receptors [45]. Stimulation of protein 
kinase C by phorbol ester also leads to activation 
of MAPK [46]. Signal transduction of trimeric G- 
protein coupled or PKC dependent MAPK activa- 
tion is not as well understood as the growth factor 
response. In the budding yeast S. cerevisiae, the 
mating pheromone response pathway is similar to 
the mammalian MAPK pathway [5]. The yeast 
pheromone receptor is coupled to trimeric G-pro- 
tein. Although how the activation of trimeric G- 
protein leads to MAPK activation is not comple- 
tely understood, interestingly, many signalling 
molecules in the yeast pheromone response and 
mammalian mitogenic growth factor response are 
highly conserved. For example, highly related 
structural homologues  of  MAPK, MEK and 
MEKK (for MEK kinase) are also found in the 
mating pathway as FUS3/KSS1, STE7 and STEl l, 
respectively [5]. Genetic studies in yeast also 
show that mult iple  pathways using dist inct  
MAPK, MEK isozymes operate in the cell (see 
review by Errede and Levine, ref. 5). These obser- 
vations clearly suggest that the MAPK cascade is 
a multidimensional pathway involved in numer- 
ous cellular responses and is highly conserved 
through evolution. 
MEK ACTIVATORS 
Raf is a serine/threonine kinase which is acti- 
vated upon growth factor stimulation. In raf trans- 
formed cells, the MAPK pathway was found to be 
constitutively activated, suggesting that raf is 
upstream of MEK [38-40[. Furthermore, direct 
biochemical evidence showed that immunoprecip- 
itated Raf can activate MEK in vitro [38-40]. C- 
Raf as a direct activator of MEK was further 
proved by the observation that purified Raf can 
phosphorylate and activate the purified MEK [47]. 
Activation of MEK and MAPK can be reconstitu- 
ted in vitro by purified recombinant proteins [47]. 
These experiments established that Raf is a direct 
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activator of MEK. However, in PC12 cells, over 
expression of Raf is not sufficient to cause an acti- 
vation of MEK and MAPK while expression of 
Ras was sufficient to induce a MEK and MAPK 
activation [48]. These data indicated that Raf may 
not be the only activator for MEK. 
Cooper  and co l leagues  have shown that 
immunoprecipitated c-Mos, a serine/threonine 
kinase, can activate MEK in vitro [49]. However, 
the c-Mos protein was exclusively found in early 
embryonic tissues and germ cells. Therefore, mos 
may be important for MEK activation in restricted 
cell types, but unlikely to play a major role in 
MEK act ivat ion in general .  The yeast  gene 
STE11, which encodes for a putative protein 
kinase, has been genetically demonstrated to func- 
tion upstream of the STE7 gene which encodes for 
a MEK homologue in the pheromone response 
pathway [50]. In an effort to search for STEll  
homologue in high eukaryotes, Johnson and col- 
leagues isolated a STEl l  related kinase from 
mouse, and named it as MEKK for MEK kinase 
[51]. MEKK has been over expressed in cultured 
cells and known to cause MEK phosphorylation 
and activation. MEKK was initially suggested to 
mediate the trimeric G-protein coupled MEK acti- 
vation due to its analogy to the yeast mating 
pheromone response. However, recent data have 
indicated that it is Ras and Raf which are activat- 
ed in the muscurinic receptor induced MAPK acti- 
vation [52]. Therefore, the trimeric G-protein cou- 
pled MEK/MAPK activation is also mediated at 
least in part by Ras and Raf which are certainly 
important for receptor tyrosine kinase induced 
MEK/MAPK activation. The role of MEKK in 
MEK activation is still an unsolved puzzle. At 
least three pathways activating MEK/MAPK 
homologues  in yeast  [5]. These include the 
pheromone response pathway, and pathways 
involved protein kinase C and osmotic regulation. 
It is likely that multiple MEK activators/kinases 
exist in higher eukaryotes. 
MAPK SUBSTRATES 
Analysis of the substrate specificity of MAPK 
using synthetic peptides demonstrates that P-X- 
S/T-P (P for proline,  X for any amino acid, 
S/T for the phosphorylation residue serine or 
threonine) represents the optimal sequence for 
MAPK phosphorylation although the first proline 
in this motif is not absolutely required [53, 54]. 
MAPK phosphorylates and regulates numerous 
cellular signalling molecules. These include cell 
surface  prote ins ,  cy toske le ta l  components ,  
cytoplasmic kinases, and nuclear transcription 
factors. MAPK phosphorylates EGF receptor 
and possibly decreases the sensitivity of  the 
receptor to EGF [55]. Phosphorylation of phos- 
pholipase A2 by MAPK increases its activity, 
therefore enhances the production of second mes- 
sage [56]. Substrates of  MAPK also include 
cytoskeletal proteins. In the case of  Xenopus 
oocytes, MAPK can cause a dramatic morphologi- 
cal change of cytoskeletal [57]. Perhaps the most 
interesting and extensively studied MAPK sub- 
strates are nuclear transcription factors, including 
c-jun, c-myc, p62 rcF and ATF2 [42-44,  58]. 
Available evidence suggests that these transcrip- 
tion factors can be phosphorylated by MAPK and 
their transcription activities are regulated by these 
phosphorylations. Therefore, one of the prominent 
effects of MAPK activation is transcriptional 
activation of numerous cellular genes essential 
for growth. Protein kinase p90 r~k is clearly one 
of the physiological substrates of MAPK [59]. 
Phosphorylation of p90 rsk by MAPK is responsible 
for its activation and has an important role in 
signal transduction. MAPKAP kinase (for MAPK 
act ivated protein kinase) is another  ser ine/  
threonine protein kinase whose activation requires 
the phosphorylation by MAPK [60]. Furthermore, 
other kinases, including MEK [61] and c-Raf 
[62] which function upstream of MAPK, are also 
phosphorylated by MAPK although the physio- 
logical significance of these phosphorylations 
is yet to be determined. However, it is certain 
that the list of  MAPK substrates  is l ikely 
to be increased as the research in this area 
progresses. The identification of important cellu- 
lar signalling molecules as the substrates of 
MAPK supports the idea that activation of MAPK 
plays a central role in regulation of cell growth 
and differentiation. 
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BIOCHEMICAL MECHANISMS OF MEK 
AND MAPK ACTIVATION 
One of the most interesting features of MAPK 
activation is that phosphorylations of both threo- 
nine and tyrosine residues are required. The 
MAPK can be completely inactivated by dephos- 
phorylation with either serine/threonine specific 
or tyrosine specific phosphatase [9, 63]. Sturgill 
and colleagues identified that threonine 183 and 
tyrosine 185 in p42mapk are the activation phos- 
phorylation sites (Fig. 2) [64, 65]. Mutation of 
either threonine 183 or tyrosine 185 using recom- 
binant p42 mapk unequivocally demonstrated that 
phosphorylation of both residue is absolutely 
required for its activation [66]. 
The requirement for both threonine and tyro- 
sine phosphorylation for MAPK activation initi- 
ally suggested a very intriguing possibility that 
MAPK may represent an integration point of sig- 
nal transduction where serine/threonine kinase 
pathway and the tyrosine kinase pathway are 
merged. However, purification and characteriza- 
tion of the MAPK kinase demonstrated that the 
threonine 183 and tyrosine 185 in MAPK were 
phosphoryla ted  by a single kinase,  MEK. 
Therefore, MEK is a dual specific kinase which 
can efficiently catalyse the phosphorylation of 
specific threonine and tyrosine in MAPK. MEK is 
an extremely specific kinase which shows a very 
high substrate selectivity toward MAPK [67]. 
Al though mult iple isozymes of  MEK exist, 
MAPK is the only identified physiological sub- 
strate of MEK, Similarly, MEK is the only activa- 
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Fig. 2. Activation of MEK and MAPK. 
tot of MAPK. This unique relationship between 
MAPK and MEK suggests that MEK is a point of 
signal integration from different pathways such as 
the activation of Raf, Mos and MEKK (Fig. 2). 
MAPK elicits cellular responses by phosphoryla- 
tion of a wide variety of target proteins. The 
kinase activity of MAPK can be activated by 
MEK as much as 1000 fold using purified recom- 
binant proteins [66]. The tyrosine 185 is also a 
major  autophosphoryla t ion  site of MAPK 
although autophosphorylation is insufficient to 
activate the kinase fully. 
The observation that MEK is the sole protein 
kinase which is responsible for MAPK activation 
generates an intense interest in MEK regulation. 
MEK activity was rapidly activated by growth 
factor and its activity declined rapidly afterwards. 
MEK activation was found to be associated with 
serine and maybe threonine phosphorylation. Two 
serine residues (Ser218 and 222) of human MEK1 
are the phosphoryla t ion sites by Raf  [68]. 
Mutation of either residue completely eliminates 
the Raf-dependent MEK activation, suggesting 
that phosphorylations of both residues are essen- 
tial for act ivat ion.  These two residues are 
absolutely conserved in all members of the MEK 
family including the yeast MEK homologues. 
Mutation of corresponding residues in yeast STE7 
showed that both residues are essential for the 
biological  funct ion of STE7 in the mating 
pheromone response. Other MEK activators, such 
as MEKK and Mos, are likely to employ the same 
mechanism in MEK activation although direct 
biochemical evidence is not available. 
It is worth noting that threonine 183 and tyro- 
sine 185 of MAPK and serine residues 218 and 
222 of MEK are located between the kinase sub- 
domain VII and VIII. Phosphorylation of residues 
in this region are also important for kinase acti- 
vity of PKA [69], cdc2 [70], and p90rsk [71]. 
Crystal graphic structure of MAPK has recently 
been solved [72]. The three dimensional structure 
of  MAPK predicts that tyrosine 185 in the 
unphosphorylated MAPK is located at a position 
which blocks the binding of peptide substrates 
[72]. Phosphorylation of this tyrosine residue and 
threonine 183 will likely induce a dramatic con- 
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formational change and allow the enzyme to bind 
substrates. One of the striking features for MAPK 
and MEK activation is the requirement of phos- 
phorylation of two residues by a single kinase. In 
contrast, activation of PKA, cdc2, and p90rsk 
only requires phosphorylation of a single residue 
between subdomain VII and VIII. The activation 
pathway of MEK/MAPK is one of the central sig- 
nal transduction pathways in the cell. This kinase 
cascade must be tightly and precisely regulated. 
The requirement  for phosphorylat ion of two 
residues is clearly beneficial to guarantee a high 
specificity and to avoid activation by nonspecific 
phosphorylation. 
PHOSPHATASE AND INACTIVATOR 
The activation of MAPK is followed by a rapid 
deactivation in EGF-stimulated Swiss3T3 cells. 
Western blot t ing with ant i -MAPK ant ibody 
demonstrated that the protein level of MAPK is 
not changed significantly during this process, sug- 
gesting that the MAPK is inactivated by post 
translational modification [73]. The activated 
MAPK displays a retarded electrophoretic mobili- 
ty shift on SDS-PAGE. The mobility shift disap- 
peared when MAPK act ivi ty  decl ined after  
growth factor stimulation. This evidence suggests 
that MAPK is inactivated by dephosphorylation. 
Trea tmen t  of  cells  with okadaic  acid in 
adipocyte causes an activation of MAPK suggest- 
ing a role of protein phosphatase 2A (PP2A) in 
this kinase cascade [74]. However, it is unclear 
whether PP2A directly dephosphorylates MAPK 
or indirect ly  regulates  kinases upst ream of  
MAPK. The okadaic acid induced MAPK activa- 
tion is not observed in other cell types, indicating 
that PP2A may not be a general MAPK inactiva- 
tor. The best candidate for MAPK phosphatase is 
a mitogen induced dual specific phosphatase 
HVH1 [75] which is also known as CL100,  
3CH134 or MKP [76--78]. 
HVH1 is an immediate  early gene whose 
mRNA is induced by serum, growth factors and 
phorbol ester [76]. The HVH1 mRNA reaches a 
maximum approximately 30 min after stimulation 
and rapidly declines thereafter. The HVH1 protein 
is also very unstable and shows an induction pat- 
tern similar to its mRNA. Biochemical characteri- 
zation of recombinant HVH1 protein shows that it 
specifically dephosphorylates the tyrosine and 
threonine  residues of  the ac t ivated  MAPK 
[75-78]. In fact HVH1 dephosphorylates MAPK 
on the same residues which are recognized by 
MEK. Furthermore, the HVH1 phosphatase dis- 
plays a remarkable substrate specificity toward the 
activated MAPK and shows little activity toward 
other phosphoproteins [75]. Further evidence sup- 
porting the role of HVH1 phosphatase in MAPK 
kinase regulation was obtained by Sun et al. [78]. 
The HVH1 phosphatase can be co-immunoprecip- 
itated with MAPK in a growth factor dependent 
fashion. This co-immunoprecipitation has been 
substantiated by the in vitro association of recom- 
binant HVH1 and MAPK. A HVH1 related pro- 
tein phosphatase, PAC1, has been isolated as an 
immediate early gene in B-lymphocyte activation 
and can also inactivate MAPK [79, 80]. PAC1 
was found to be localized into the nucleus. The 
nuclear localization of PAC1 is particularly inter- 
esting because the activated MAPK is also accu- 
mulated in the cell nucleus. 
A VH1 related phosphatase gene, MSG5, has 
been isolated in S. cerevisiae to suppress the 
pheromone response pathway [81]. The MSG5 
mRNA is induced by addi t ion of  mating 
pheromone. Furthermore, the MSG5 gene product 
can dephosphorylate and inactivate the FUS3 
kinase. Both genetic data in yeast and biochemical 
data from mammalian cells show that the MAPK 
pathway is regulated by the balanced actions of 
specific kinases and phosphatases. 
CONCLUDING REMARKS 
The MAPK activation pathway is one of the 
central schemes in signal transduction. A linear 
pathway from the cell surface to cytoplasmic and 
nuclear events has just emerged (Fig. 1). Despite 
rapid progress in the last few years, numerous 
important questions remain to be clarified. It is 
unclear how Raf is activated although the associa- 
tion of Ras and Raf is likely to be an important 
event. MAPK is activated in mitogenic growth 
The mitogen activated protein kinase signal transduction pathway 587 
factors as well as in factors which induce differen- 
tiation. For  example,  both EGF and NGF induce 
M A P K  activation in PC12 cells, yet EGF causes 
pro l i fe ra t ion  whi le  N G F  causes different ia t ion.  
Therefore the role of  M A P K  activation in these 
apparent  opposi te  effects in the cells is obscure. 
Several  different M E K  activators, including Raf, 
Mos and MEKK,  have been discovered. The rela- 
t ionship  be tween  dif ferent  M E K  act ivators  and 
different extracellular  stimuli are not completely 
resolved. Furthermore, both M A P K  and MEK are 
mult iple enzyme families,  and the physiological  
function of  each isozyme in signal transduction is 
not  unders tood.  W e  know very  l i t t le  about  the 
inactivation of  this kinase cascade, especial ly in 
inact ivat ion of  M E K  and Raf. Study to identify 
the negative regulators of  the M A P K  pathway will 
l ikely yield fruitful results in the regulation of this 
kinase cascade. 
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